Didactics-Chemotherapy Response Score_Pathologist perspecitive_Angela Ralte_June 2021

Chemotherapy Response Score_Pathologist perspecitive_Angela Ralte_June 2021_ India

Video Transcription

Video Summary

In this video, Angela Ralte, a gynaecological pathologist, discusses the chemotherapy response score (CRS) system for assessing the response of ovarian carcinomas to neoadjuvant chemotherapy. She begins by explaining the two main treatment options for high-grade ovarian epithelial cancers: primary debulking surgery followed by chemotherapy, or neoadjuvant chemotherapy followed by surgery. She then delves into the details of the CRS system, which is a three-tiered numerical code used to assess the response to chemotherapy. Angela provides examples and images to illustrate each score: CRS1 (no or minimal response), CRS2 (appreciable response with viable tumor), and CRS3 (complete or near-complete response with minimal residual tumor). She also mentions practical challenges and limitations of the CRS system, such as assessing cases with no tumor bed and cases with different responses in different tissues. Angela concludes by emphasizing the importance of the CRS system for predicting survival and informing patient care in ovarian cancer. The video was presented by Angela Ralte.

Keywords

chemotherapy response score

CRS system

ovarian carcinomas

neoadjuvant chemotherapy

primary debulking surgery

high-grade ovarian epithelial cancers